Merus NV
MRUS66.269USD
+0.709+1.08%
Horário de mercado （ET）Cotações atrasadas em 15 min
4.58BValor de mercado
PerdaP/L TTM
Mais detalhes de Merus NV Empresa
Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The company operates in the Netherlands and United States.
Informações da empresa
Código da empresaMRUS
Nome da EmpresaMerus NV
Data de listagemMay 19, 2016
CEODr. Sven Ante (Bill) Lundberg, M.D.
Número de funcionários260
Tipo de títulosOrdinary Share
Fim do ano fiscalMay 19
EndereçoUppsalalaan 17, 3rd & 4th floor
CidadeUTRECHT
Bolsa de valoresNASDAQ Global Market Consolidated
PaísNetherlands
Código postal3584 CT
Telefone31850162500
Sitehttps://merus.nl/
Código da empresaMRUS
Data de listagemMay 19, 2016
CEODr. Sven Ante (Bill) Lundberg, M.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Sven Ante (Bill) Lundberg, M.D.
Dr. Sven Ante (Bill) Lundberg, M.D.
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
198.74K
+55.46%
Dr. Anand Mehra, M.D.
Dr. Anand Mehra, M.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Peter B. Silverman, J.D.
Mr. Peter B. Silverman, J.D.
Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal
Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal
--
--
Ms. Sherri Spear
Ms. Sherri Spear
Investor Relations and Corporate Communications
Investor Relations and Corporate Communications
--
--
Mr. Jason Haddock
Mr. Jason Haddock
Director
Director
--
--
Dr. Fabian Zohren, M.D., Ph.D
Dr. Fabian Zohren, M.D., Ph.D
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Maxine Gowen, Ph.D.
Dr. Maxine Gowen, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Leonard (Len) Kanavy
Mr. Leonard (Len) Kanavy
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Victor Sandor, M.D.
Dr. Victor Sandor, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Gregory D. (Greg) Perry
Mr. Gregory D. (Greg) Perry
Chief Financial Officer
Chief Financial Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Sven Ante (Bill) Lundberg, M.D.
Dr. Sven Ante (Bill) Lundberg, M.D.
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
198.74K
+55.46%
Dr. Anand Mehra, M.D.
Dr. Anand Mehra, M.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Peter B. Silverman, J.D.
Mr. Peter B. Silverman, J.D.
Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal
Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal
--
--
Ms. Sherri Spear
Ms. Sherri Spear
Investor Relations and Corporate Communications
Investor Relations and Corporate Communications
--
--
Mr. Jason Haddock
Mr. Jason Haddock
Director
Director
--
--
Dr. Fabian Zohren, M.D., Ph.D
Dr. Fabian Zohren, M.D., Ph.D
Chief Medical Officer
Chief Medical Officer
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 17 de mai
Atualizado em: sáb, 17 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Fidelity Management & Research Company LLC
7.55%
Wellington Management Company, LLP
6.34%
Commodore Capital LP
6.01%
RTW Investments L.P.
5.60%
Paradigm BioCapital Advisors LP
4.77%
Other
69.72%
Investidores
Investidores
Proporção
Fidelity Management & Research Company LLC
7.55%
Wellington Management Company, LLP
6.34%
Commodore Capital LP
6.01%
RTW Investments L.P.
5.60%
Paradigm BioCapital Advisors LP
4.77%
Other
69.72%
Tipos de investidores
Investidores
Proporção
Investment Advisor/Hedge Fund
35.42%
Hedge Fund
34.84%
Investment Advisor
23.80%
Corporation
1.96%
Research Firm
1.56%
Venture Capital
1.48%
Private Equity
1.43%
Individual Investor
0.38%
Pension Fund
0.36%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
409
75.54M
101.47%
-10.37M
2025Q1
420
74.82M
101.12%
-10.15M
2024Q4
398
74.69M
108.18%
-7.45M
2024Q3
373
72.99M
107.03%
-6.71M
2024Q2
355
69.91M
103.77%
+7.77M
2024Q1
315
57.35M
97.63%
-5.32M
2023Q4
282
57.36M
99.41%
-5.55M
2023Q3
268
57.60M
100.50%
+2.76M
2023Q2
260
49.90M
100.83%
+114.35K
2023Q1
250
43.88M
95.34%
-4.11M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Fidelity Management & Research Company LLC
5.62M
7.55%
-39.01K
-0.69%
Mar 31, 2025
Wellington Management Company, LLP
4.72M
6.34%
+1.22M
+34.90%
Mar 31, 2025
Commodore Capital LP
4.47M
6.01%
+598.66K
+15.45%
Mar 31, 2025
RTW Investments L.P.
4.17M
5.6%
--
--
Mar 31, 2025
Paradigm BioCapital Advisors LP
3.55M
4.77%
+184.36K
+5.47%
Apr 03, 2025
Deerfield Management Company, L.P.
3.17M
4.26%
+201.14K
+6.77%
Mar 31, 2025
Avoro Capital Advisors LLC
3.00M
4.03%
+875.00K
+41.18%
Mar 31, 2025
Samlyn Capital, LLC
2.38M
3.2%
-288.75K
-10.82%
Mar 31, 2025
Franklin Advisers, Inc.
1.94M
2.6%
+3.50K
+0.18%
Mar 31, 2025
Holocene Advisors, LP
1.87M
2.52%
-6.39K
-0.34%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
Tema Oncology ETF
3.92%
ALPS Medical Breakthroughs ETF
2.65%
Invesco Dorsey Wright Healthcare Momentum ETF
1.51%
Harbor Health Care ETF
1.1%
First Trust IPOX Europe Equity Opportunities ETF
1.04%
Virtus LifeSci Biotech Clinical Trials ETF
0.85%
JPMorgan Healthcare Leaders ETF
0.62%
ProShares Ultra Nasdaq Biotechnology
0.41%
Invesco Nasdaq Biotechnology ETF
0.41%
First Trust Multi-Manager Small Cap Opportunities ETF
0.39%
Ver Mais
Tema Oncology ETF
Proporção3.92%
ALPS Medical Breakthroughs ETF
Proporção2.65%
Invesco Dorsey Wright Healthcare Momentum ETF
Proporção1.51%
Harbor Health Care ETF
Proporção1.1%
First Trust IPOX Europe Equity Opportunities ETF
Proporção1.04%
Virtus LifeSci Biotech Clinical Trials ETF
Proporção0.85%
JPMorgan Healthcare Leaders ETF
Proporção0.62%
ProShares Ultra Nasdaq Biotechnology
Proporção0.41%
Invesco Nasdaq Biotechnology ETF
Proporção0.41%
First Trust Multi-Manager Small Cap Opportunities ETF
Proporção0.39%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
